Machine Learning Models Demonstrate High Diagnostic Accuracy for Cardiac Amyloidosis DetectionMachine learning shows promise for diagnosing cardiac amyloidosis

Frontiers in Medicine Published August 4, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Machine learning models show high sensitivity and specificity for diagnosing both AL-CA and ATTR-CA subtypes.

This meta-analysis evaluated the diagnostic performance of various machine learning (ML) models across 30 studies to identify cardiac amyloidosis. The analysis specifically focused on distinguishing between light chain (AL-CA) and transthyretin (ATTR-CA) subtypes, which are critical for determining appropriate treatment pathways.

Overall results indicated strong diagnostic accuracy for cardiac amyloidosis, with a reported sensitivity of 0.87 and specificity of 0.88. The SROC AUC reached 0.93, suggesting that ML models can effectively identify patients with these conditions compared to standard clinical assessments.

Subgroup analyses revealed high performance for both AL-CA (sensitivity 0.85) and ATTR-CA (sensitivity 0.84). Even models relying solely on echocardiography demonstrated robust metrics, achieving a specificity of 0.86 and an AUC of 0.88.

While the data suggests that ML tools are highly effective for screening and diagnosis, clinicians should interpret these findings with caution. The current evidence base contains inherent methodological limitations, meaning these models are not yet established as standardized clinical protocols.

How this fits prior evidence

This meta-analysis extends previous findings regarding machine learning applications in cardiac amyloidosis. It complements the finding that the Amylo-Detect model detects cardiac amyloidosis on bone scintigraphy with high accuracy and the observation that RELAPS pattern diagnostic accuracy varies by software platform. While these studies highlight specific modalities, this meta-analysis provides a broader overview of ML performance across multiple subtypes (AL-CA and ATTR-CA) and imaging types.

Detecting certain heart conditions early is vital for patients with cardiac amyloidosis. This condition occurs when proteins build up in the heart muscle, making it harder for the heart to pump blood. Because these cases can be complex to identify, researchers looked at how machine learning—a type of artificial intelligence—could help doctors make more accurate diagnoses.

By looking at 30 different studies, researchers found that machine learning models performed well in identifying both light chain and transthyretin types of the disease. For example, these tools showed a high accuracy rate for overall cases. They also showed strong results when using only ultrasound images to spot the condition.

While the numbers are encouraging, it is important to remember that these tools are not yet standard in every clinic. The findings come from studies with different qualities and methods, so doctors should still use these results as a helpful guide rather than a final word. These tools show potential for helping doctors catch heart issues sooner.

What this means for you:

Machine learning models show high accuracy in identifying heart conditions caused by protein buildup.

Common questions

How accurate is machine learning at finding heart disease?

Machine learning shows high accuracy for diagnosing cardiac amyloidosis. In the studies reviewed, these models showed a sensitivity of 0.87 and a specificity of 0.88 for overall cases. This means they are quite effective at correctly identifying the condition when it is present.

Can machine learning identify specific types of heart issues?

Yes, these models can distinguish between different types. For light chain amyloidosis, the accuracy was 0.85 for sensitivity and 0.82 for specificity. For transthyretin amyloidosis, the tools showed a sensitivity of 0.84 and a specificity of 0.85.

Is machine learning used in clinics today?

While these models show favorable accuracy, they are not yet a standard tool in every clinic. Because the evidence comes from 30 studies with varying quality and methods, doctors should interpret these results carefully as they work toward better diagnostic tools.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJul 2026

View Original Abstract ↓

BackgroundCardiac amyloidosis (CA) is an infiltrative restrictive cardiomyopathy characterized by the deposition of β-fold amyloid, often presenting as left ventricular hypertrophy. Early nonspecific symptoms lead to frequent misdiagnosis as hypertrophic cardiomyopathy, delaying care for this progressive disease. While machine learning (ML) has been applied to the diagnosis of CA, systematic evidence of its accuracy remains lacking, hindering the development of intelligent detection tools.ObjectivesTo explore the diagnostic accuracy of ML, providing evidence-based data to advance smart detection tools for CA.MethodsWe searched the Cochrane Library, PubMed, Embase, and Web of Science up to September 25, 2025, adhering to PRISMA 2020 guidelines. Study quality was evaluated using the QUADAS-2 instrument. Subgroup analyses were stratified by disease type [light chain CA (AL-CA), transthyretin CA (ATTR-CA)] and imaging modality (echocardiography) to explore sources of heterogeneity and assess diagnostic performance across different clinical scenarios.ResultsThe current meta-analysis incorporated 30 studies. In validation sets, ML for overall CA showed sensitivity 0.87 [95% confidence interval (CI) 0.83–0.91], specificity 0.88 (95% CI: 0.81–0.92), positive likelihood ratio (PLR) 7.0 (95% CI: 4.4–11.4), negative likelihood ratio (NLR) 0.14 (95% CI: 0.10–0.20), and SROC AUC 0.93 (95% CI: 0.91–0.95). For AL-CA, ML demonstrated sensitivity 0.85 (95% CI: 0.76–0.91), specificity 0.82 (95% CI: 0.75–0.87), PLR 4.8 (95% CI: 3.4–6.7), NLR 0.18 (95% CI: 0.11–0.30), and SROC AUC 0.88 (95% CI: 0.85–0.91). For ATTR-CA, ML revealed sensitivity 0.84 (95% CI: 0.77–0.89), specificity 0.85 (95% CI: 0.78–0.91), PLR 5.7 (95% CI: 3.6–9.2), NLR 0.19 (95% CI: 0.12–0.28), and SROC AUC 0.91 (95% CI: 0.88–0.93). Echocardiography-only ML models showed sensitivity 0.83 (95% CI: 0.81–0.85), specificity 0.86 (95% CI: 0.82–0.89), PLR 5.9 (95% CI: 4.4–7.9), NLR 0.20 (95% CI: 0.17–0.23), and SROC AUC 0.88 (95% CI: 0.85–0.91).ConclusionsML demonstrates favorable diagnostic accuracy for CA. Nevertheless, the aggregated findings warrant cautious interpretation owing to inherent methodological limitations in the existing evidence. Future investigations incorporating diverse cases from broader geographic regions are needed to further validate the diagnostic performance of ML for CA and to advance the subsequent development of assessment tools based on artificial intelligence.Systematic Review RegistrationPROSPERO CRD42024536601.

Machine Learning Models Demonstrate High Diagnostic Accuracy for Cardiac Amyloidosis DetectionMachine learning shows promise for diagnosing cardiac amyloidosis

How this fits prior evidence

Common questions

Study Details

Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk

People with lupus face higher heart disease risk but genetics show no direct link

Clinical research that matters. Delivered to your inbox.

Machine Learning Models Demonstrate High Diagnostic Accuracy for Cardiac Amyloidosis DetectionMachine learning shows promise for diagnosing cardiac amyloidosis

How this fits prior evidence

Common questions

More on Cardiac Amyloidosis

Study Details

Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk

People with lupus face higher heart disease risk but genetics show no direct link

Clinical research that matters. Delivered to your inbox.

Related in Cardiology

From Other Specialties